Key takeaways
Foundayo (orforglipron) and Zepbound (tirzepatide) are both medications used for weight loss in adults who are obese or overweight with at least one weight-related condition. They belong to the class of GLP-1 agonists, but Zepbound is also a GIP agonist. Foundayo is taken orally once a day, while Zepbound is injected under the skin once a week. Foundayo is available as a tablet, whereas Zepbound comes in injectable forms like vials and pens. Foundayo is only approved for weight loss, while Zepbound is also approved for treating moderate-to-severe sleep apnea. Both medications can cause side effects like nausea and diarrhea, but Zepbound may also cause injection site reactions. Neither medication is available as a generic. Foundayo can interact with other oral medications by affecting their absorption, while Zepbound can interact with insulin, increasing the risk of low blood sugar.
